Search results
The QUADRIC Study
Added:
9 months ago
Article
The QFR-DECISION-PCI Study
Added:
1 year ago
Article
Added:
2 months ago
Added:
1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
1 year ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure…
View more
Added:
1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive…
View more
Added:
11 months ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB…
View more
Start date:
Apr 23, 2025
This webinar brings together leading experts Dr Rodrigo Bagur, Dr Angela McInerney, Dr Rolf Kreutz, Dr Sohail Khan, Dr Sophia Khattak, Dr Jonathan Hinton and Dr Peter O’Kane to explore the challenges and solutions in managing calcified coronary artery disease. The session will provide a detailed examination of coronary calcification from pathological and clinical perspectives, including…
View more